Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) Short Interest Up 260.9% in June

Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) was the recipient of a significant increase in short interest during the month of June. As of June 15th, there was short interest totaling 208,401 shares, an increase of 260.9% from the May 31st total of 57,741 shares. Based on an average trading volume of 1,239,748 shares, the short-interest ratio is currently 0.2 days. Approximately 1.9% of the company’s stock are sold short.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Hong Kong Pharma Digital Technology stock. StoneX Group Inc. bought a new position in Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 43,284 shares of the company’s stock, valued at approximately $36,000. StoneX Group Inc. owned about 0.39% of Hong Kong Pharma Digital Technology as of its most recent filing with the Securities and Exchange Commission (SEC).

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Hong Kong Pharma Digital Technology in a research report on Friday, May 1st. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Hong Kong Pharma Digital Technology currently has an average rating of “Sell”.

Hong Kong Pharma Digital Technology Stock Up 9.4%

NASDAQ:HKPD traded up $0.03 during trading hours on Monday, reaching $0.40. The company had a trading volume of 13,521 shares, compared to its average volume of 205,727. The company has a current ratio of 2.93, a quick ratio of 2.73 and a debt-to-equity ratio of 0.28. Hong Kong Pharma Digital Technology has a 52 week low of $0.32 and a 52 week high of $2.58. The firm’s 50 day moving average price is $0.54 and its 200-day moving average price is $0.66.

About Hong Kong Pharma Digital Technology

Hong Kong Pharma is an exempted limited liability company formed under the laws of the Cayman Islands on August 17, 2023. As a holding company with no material operations of its own, Hong Kong Pharma conducts its operations through its wholly owned subsidiaries, Joint Cross Border Logistics Company Limited and V-Alliance Technology Supplies Limited, each a limited liability corporation incorporated in Hong Kong and collectively referred to as HK Subsidiaries. Our business offering consists of two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, primarily conducted through our Hong Kong subsidiary, Joint Cross Border, which we refer to as the “Supply Chain Services” division and (ii) OTC pharmaceutical cross-border procurement and distribution, primarily conducted through our Hong Kong subsidiary, V-Alliance, which we refer to as the “Procurement and Distribution” division.